NCT01036854View on ClinicalTrials.gov

Pharmacokinetic Study of Ondansetron Administered as IR (Zofran) and MR (EUR1025)

PHASE1CompletedINTERVENTIONAL
Enrollment

128

Participants

Timeline

Start Date

February 28, 2009

Primary Completion Date

April 30, 2009

Study Completion Date

April 30, 2009

Conditions
Nausea
Interventions
DRUG

EUR-1025

orally, 24 mg, daily for 6 days

DRUG

EUR-1025

orally, 8 mg, twice daily over 6 consecutive days

DRUG

EUR-1025

orally, 8 mg, three times a day over 6 consecutive days

DRUG

EUR-1025

orally, 8 mg, 16 mg, 24 mg, daily, for 6 days

Trial Locations (1)

H3P 3PI

Algorithme Pharma INc., Mount Royal

Sponsors
All Listed Sponsors
lead

Forest Laboratories

INDUSTRY